Dublin, July 29, 2020 (GLOBE NEWSWIRE) -- The "Hemophagocytic Lymphohistiocytosis Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Hemophagocytic Lymphohistiocytosis Overview

Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems. HLH is a condition with different underlying causes.

The onset and severity of hemophagocytic lymphohistiocytosis can vary greatly from one person to another. Generally, affected individuals develop fevers, a rash, an abnormally large liver (hepatomegaly), and an abnormally large spleen (splenomegaly). However, these initial sign and symptoms are described as nonspecific. Affected individuals may also have anemia, thrombocytopenia, neurological symptoms including seizures, changes in mental status and irritability, paralysis (palsy) of certain cranial nerves, and problems coordinating voluntary movements (ataxia).

Hemophagocytic Lymphohistiocytosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Hemophagocytic Lymphohistiocytosis market for the treatment of the condition. It also provides the country-wise Hemophagocytic Lymphohistiocytosis treatment guidelines across the United States, Europe and Japan.

The Hemophagocytic Lymphohistiocytosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Hemophagocytic Lymphohistiocytosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Hemophagocytic Lymphohistiocytosis Epidemiology

The Hemophagocytic Lymphohistiocytosis epidemiology chapters provide insights about historical and current Hemophagocytic Lymphohistiocytosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Hemophagocytic Lymphohistiocytosis epidemiology is segmented by Incidence of Hemophagocytic Lymphohistiocytosis (Familial and secondary HLH), Familial HLH cases by Mutation Types and Secondary HLH cases by Etiologies. The report includes a thorough analysis of all segmentations.

Incidence of Hemophagocytic Lymphohistiocytosis can be divided into two subtypes: familial or primary HLH cases and secondary HLH cases. In the US, the cases of familial Hemophagocytic Lymphohistiocytosis were found to be 100 in 2017. Moreover, the cases of secondary HLH were reported to be 315 in the country.

According to the publisher's, the total incident population of Hemophagocytic Lymphohistiocytosis in seven major markets was 4,435 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, Germany accounts for the highest number of Hemophagocytic Lymphohistiocytosis cases.

Hemophagocytic Lymphohistiocytosis Market Outlook

The Hemophagocytic Lymphohistiocytosis market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, France accounts for the largest Hemophagocytic Lymphohistiocytosis market size with USD 1.3 million in 2017, while Japan had the smallest market size of HLH with USD 0.2 million in 2017.

Hemophagocytic Lymphohistiocytosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Hemophagocytic Lymphohistiocytosis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hemophagocytic Lymphohistiocytosis market uptake by drugs; patient uptake by therapies; and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of HLH market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hemophagocytic Lymphohistiocytosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Report Highlights

Hemophagocytic Lymphohistiocytosis Report Insights

Hemophagocytic Lymphohistiocytosis Report Key Strengths

Hemophagocytic Lymphohistiocytosis Report Assessment

Reasons to buy

Key Topics Covered:

1 Key Insights

2 Executive Summary of Hemophagocytic Lymphohistiocytosis

3 SWOT Analysis for HLH

4 Hemophagocytic Lymphohistiocytosis Market Overview at a Glance
4.1 Market Share (%) Distribution of Hemophagocytic Lymphohistiocytosis in 2017
4.2 Market Share (%) Distribution of Hemophagocytic Lymphohistiocytosis in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 History
5.3 Classification
5.4 Sub-types
5.5 Causes
5.6 Symptoms
5.7 Clinical Presentation
5.8 Pathophysiology
5.9 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale - 7MM
6.3 7MM Total Incident Patient Population of Hemophagocytic Lymphohistiocytosis

7 Country Wise-Epidemiology of Hemophagocytic Lymphohistiocytosis
7.1 The United States
7.1.1 Total Incident Cases of Hemophagocytic Lymphohistiocytosis in the United States
7.1.2 Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in the United States
7.1.3 Secondary HLH Cases by Etiologies in the United States
7.2 EU5
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 Spain
7.2.5 The United Kingdom
7.2.6 Japan

8 Treatment
8.1 Guidelines
8.1.1 HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis
8.1.2 Management of Hemophagocytic Lymphohistiocytosis

9 Unmet Needs

10 Organizations contributing toward Hemophagocytic Lymphohistiocytosis

11 KOL's Views: Hemophagocytic Lymphohistiocytosis

12 Case Studies
12.1 Fever of Unknown Origin
12.2 A Challenging Diagnosis

13 Marketed Drugs
13.1 Gamifant (Emapalumab): Swedish Orphan Biovitrum
13.1.1 Product Description
13.1.2 Product Developmental Activity
13.1.3 Clinical Development
13.1.4 Safety and Efficacy

14 Emerging Therapies
14.1 Tadekinig alfa (IL-18BP): AB2 Bio
14.1.1 Drug Description
14.1.2 Other Developmental Activities
14.1.3 Clinical Development

15 Hemophagocytic Lymphohistiocytosis: Seven Major Market Analysis
15.1 Key Findings
15.1 Hemophagocytic Lymphohistiocytosis: Market Outlook
15.2 Market Size of Hemophagocytic Lymphohistiocytosis in 7MM

16 Market Outlook by Country
16.1 United States Market Size
16.1.1 Total Market Size of Hemophagocytic Lymphohistiocytosis
16.1.2 Total Market Size of Familial HLH
16.1.3 Total Market Size of Secondary HLH
16.2 EU-5 Countries: Market
16.2.1 Germany
16.2.2 France
16.2.3 Italy
16.2.4 Spain
16.2.5 United Kingdom
16.3 Japan: Market
16.3.1 Total Market Size of Hemophagocytic Lymphohistiocytosis
16.3.2 Total Market Size of Familial HLH
16.3.3 Total Market Size of Secondary HLH

17 Market Drivers

18 Market Barriers

19 Appendix
19.1 Report Methodology
19.2 Bibliography

20 Capabilities

21 Disclaimer

22 About the Publisher

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/k3txax

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900